Tag results:

protein expression

Investigation into the Role of Stmn2 in Vascular Smooth Muscle Phenotype Transformation during Vascular Injury via RNA Sequencing and Experimental Validation

[Environmental Science and Pollution Research] Researchers examined the effects of Stmn2 on phenotype transformation of vascular smooth muscle in vascular injury via RNA sequencing and experimental validation.

Carbonic Anhydrase III Attenuates Hypoxia-Induced Apoptosis and Activates PI3K/Akt/mTOR Pathway in H9c2 Cardiomyocyte Cell Line

[Cardiovascular Toxicology] To investigate the role of CAIII in the apoptosis of myocytes under hypoxic conditions and facilitate the strategy for treating hypoxia-induced damage, in vitro experiments in H9c2 were employed.

Silencing of Ceramide Synthase 2 in Hepatocytes Modulates Plasma Ceramide Biomarkers Predictive of Cardiovascular Death

[Molecular Therapy] Scientists discovered that the hepatocyte-specific antisense oligonucleotide triggered a parallel modulation of blood plasma ceramides, revealing that the biomarkers predictive of cardiovascular death were governed by ceramide biosynthesis in hepatocytes.

Long Non-Coding RNA MALAT1 Enhances Angiogenesis during Bone Regeneration by Regulating the miR-494/SP1 Axis

[Laboratory Investigation] Scientists explored the underlying mechanism of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1)-regulated angiogenesis during bone regeneration.

Hemin Activation Abrogates Mycoplasma hyorhinis Replication in Chronically Infected Prostate Cancer Cells via Heme Oxygenase-1 Induction

[FEBS Openbio] Researchers described the striking >90% inhibitory effect of hemin, a natural inducer of the cytoprotective enzyme heme oxygenase-1, on M. hyorhinis replication in chronically infected LNCaP prostate cancer cells.

Fulcrum Therapeutics Announces Positive Interim Results from Phase I Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

[Fulcrum Therapeutics, Inc.] Fulcrum Therapeutics, Inc. announced positive interim results from the ongoing single- and multiple-ascending dose Phase I trial with FTX-6058 in healthy adult volunteers.

Popular